Insights about U.S. Stocks that landed in the Red-Zone during Tuesday’s trade, are depicted underneath:

FuelCell Energy Inc (NASDAQ:FCEL) declined - 3.76%, and closed at $1.28.

FuelCell Energy Inc. (FCEL), a global leader in the design, manufacture, operation and service of ultra-clean, efficient and reliable fuel cell power plants, formerly on February 27, stated the closing of its formerly declared definitive contract to sell a 1.4 megawatt fuel cell power plant project at the University of Bridgeport to NRG Energy, Inc. (NRG). Concurrent with the closing, a partner of NRG, NRG Yield, Inc. (NYLD), attained the project; the first-ever fuel cell project placed into any yieldco. The University of Bridgeport will buy the electricity and heat produced by the fuel cell power plant under a multi-year power purchase contract (PPA). FuelCell Energy developed the project and is in the process of concluding the installation of the power plant. FuelCell Energy will perform operation and maintenance services for the installation over the multi-year term of NRG Yield’s PPA with the University. The power plant construction is mechanically complete and commercial operation is predictable in March 2015.

“This project is a compelling model where the University pays NRG Yield for the clean power it receives while averting the need to invest in the power generation asset itself,” said Michael Bishop, Chief Financial Officer, FuelCell Energy, Inc. “The University also benefits by enhancing the resiliency of its power supply in a low carbon manner that is almost completely absent of the pollutants that generate smog, acid rain and that can aggravate asthma.”

FuelCell Energy, Inc., together its auxiliaries, designs, manufactures, sells, installs, operates, and services stationary fuel cell power plants for distributed power generation.

Stryker Corporation (NYSE:SYK)’s shares dwindled -3.72%, and closed at $92.44.

Stryker Corporation (SYK), declared that its Board of Directors has authorized a new $2 billion share repurchase program. The program is in addition to $583 million of existing authorization remaining under the Corporation`s current share repurchase programs, bringing the Corporation`s total share repurchase authorization to $2.583 billion.

We remain committed to pursuing a capital allocation strategy that comprises attainments, dividends and share repurchases,” said Kevin A. Lobo, Chairman and Chief Executive Officer. “While M&A activity across the breadth of our product and service offerings will remain the primary focus of our long-term growth strategy, this new authorization recognizes that the strength of our balance sheet is sufficient to enable more noteworthy share repurchases. We believe that efficiently deploying our balance sheet will enable growth in sales and earnings and maximize shareholder returns.”

The share repurchases will occur at such times and prices as the Corporation determines and may be effected through transactions in the open market, privately negotiated transactions, accelerated share repurchase programs or otherwise.

Stryker Corporation, together with its auxiliaries, operates as a medical technology corporation. The corporation operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine.

Finisar Corporation (NASDAQ:FNSR), dipped -3.66%, and closed at $20.55. The company has the market capitalization of $2.19B. The beta value of the stock is 1.94. On the other hand the stock’s volatility for the week is 2.73% and for the month is 3.01%. The stock price to book value is $1.96; however price to sale value is $1.74. Analyst’s mean recommendation regarding this stock is 2.50. (where 1=Buy, 5=Sale).

Finisar Corporation provides optical subsystems and components for data communication and telecommunication applications in the United States, Malaysia, China, and internationally.

Dyax Corp (NASDAQ:DYAX), dropped -3.59%, and closed at $15.15.

Dyax Corp. (DYAX), formerly on February 24, declared financial results for the fourth quarter and year ended December 31, 2014. Dyax will host a webcast and conference call at 8:30 a.m. (ET) recently to review financial results and provide updates regarding its key value drivers – counting the KALBITOR® (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio (LFRP).

Recent highlights comprise:

• Completion of dosing in the expanded Phase 1b study of DX-2930 in hereditary angioedema (HAE) patients;
• KALBITOR net sales were $18.9 million for the fourth quarter of 2014 and $68.3 million for the full year;
• Commencement in 2014 of royalty proceed based on sales of Eli Lilly and Corporation’s CYRAMZA® (ramucirumab), the first approved therapeutic product from the LFRP; and
• Cash, cash equivalents and investments at December 31, 2014 totaled $184.7 million.

Dyax Corp., a biopharmaceutical corporation, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and plasma kallikrein-mediated (PKM) angioedemas.